$59.81
+6.84 (+12.91%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CRSP is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
13 interventional · 1 observational · 1 with posted results
Held by 10 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, D. E. Shaw & Co., Inc., CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, MILLENNIUM MANAGEMENT LLC, +5 more) · FINRA short interest 11.5 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular TherapiesNCT06208878observationalThe incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment. | — | Enrolling by invitation | Other: Non Interventional | Hematologic Malignancy, Solid Malignancy | 70 | Aug 2038 | ≤ 4,394 d | 2025-08-14 |
| Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune DiseaseNCT07549698To evaluate the safety of CTX112 in adult participants with refractory hematologic autoimmune diseases, including ITP or wAIHA.Open-label · Treatment | Phase 1/2 | Recruiting | Biological: CTX112 | Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura | 60 | Dec 2033 | ≤ 2,690 d | 2026-07-22 |
| A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune DiseaseNCT06925542To evaluate the safety of CTX112 in adult subjects with refractory autoimmune diseases, including SLE, SSc or IIMOpen-label · Treatment | Phase 1 | Recruiting | Biological: CTX112 | SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis | 80 | 2031-12-31 | in 1,959 d | 2026-08-07 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell MalignanciesNCT05643742Phase 1 (Dose Escalation): Incidence of adverse events, defined as dose-limiting toxicitiesOpen-label · Treatment | Phase 1/2 | Recruiting | Biological: CTX112 | B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Large B-cell Lymphoma | 120 | Jan 2030 | ≤ 1,260 d | 2025-11-14 |
| A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With HypertensionNCT07758634Phase 1: Incidence of dose-limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: CTX340, Placebo | Hypertension | 69 | 2028-07-01 | in 681 d | 2026-08-11 |
| A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory DyslipidemiasNCT07491172To evaluate the safety of CTX310 in adult subjects with dyslipidemias that are refractory to available treatmentsOpen-label · Treatment | Phase 1 | Recruiting | Drug: CTX310 | Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (sHTG), Mixed Hyperlipemia, Hypercholesterolaemia | 90 | Jun 2027 | ≤ 314 d | 2026-07-23 |
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic MalignanciesNCT06492304Phase 1 Part A (dose escalation) and Part B (dose optimization in selected disease types):Open-label · Treatment | Phase 1/2 | Completed | Biological: CTX131 | T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia | 12 | 2026-03-11actual | — | 2026-04-03 |
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid TumorsNCT05795595Phase 1 (Dose Escalation): Incidence of adverse eventsOpen-label · Treatment | Phase 1/2 | Completed | Biological: CTX131 | Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma | 19 | 2025-09-18actual | — | 2025-11-26 |
| An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1DNCT05565248Incidence of adverse events with causality related to VCTX211 units, the surgical procedures and/or medical interventions required to implant and explant the VCTX211 units.Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Patients to be followed up in the VCTX-201 study | Combination product: VCTX211 | Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases | 5 | 2025-08-08actual | — | 2026-05-07 |
| A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)NCT04438083Part A (dose escalation): Incidence of adverse eventsOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Patients to be followed up in the CRSP-ONC-LTF study | Biological: CTX130 | Renal Cell Carcinoma | 19 | 2024-10-08actual | — | 2025-01-08 |
| A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)NCT04035434results2025-10-24Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL PopulationOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Patients to be followed up in the CRSP-ONC-LTF study | Biological: CTX110 | B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL | 93 | 2024-10-04actual | — | 2025-10-24 |
| A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)NCT04502446Part A (dose escalation)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Patients to be followed up in the CRSP-ONC-LTF study | Biological: CTX130 | T Cell Lymphoma | 49 | 2024-08-30actual | — | 2025-01-08 |
| A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple MyelomaNCT04244656Part A (dose escalation): Incidence of adverse eventsOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Patients to be followed up in the CRSP-ONC-LTF study | Biological: CTX120 | Multiple Myeloma | 26 | 2024-01-04actual | — | 2025-01-08 |
| An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1DNCT05210530Incidence of adverse events with causality related to VCTX210A units and/or the surgical procedures required to implant and explant the VCTX210A units.Open-label · Treatment | Phase 1 | Completed | Combination product: VCTX210A unit | Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases | 7 | 2023-01-19actual | — | 2023-06-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19